MU1140

produced by the JH1140 strain of the oral bacterium Streptococcus mutansin, in preclinical development for the treatment of Gram-positive infections; structure in first source

Networked: 5 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hillman, Jeffrey D: 2 articles (11/2019 - 05/2010)
2.	Derendorf, Hartmut: 2 articles (05/2010 - 01/2009)
3.	Handfield, Martin: 1 article (11/2019)
4.	Kirichenko, Kostyantyn: 1 article (11/2019)
5.	Park, Jae H: 1 article (11/2019)
6.	Sandiford, Stephanie Kate: 1 article (04/2015)
7.	Ghobrial, Oliver: 1 article (05/2010)
8.	Ghobrial, Oliver G: 1 article (01/2009)
9.	Hillman, Jeffery D: 1 article (01/2009)

Related Diseases

1.	Infections 01/01/2022 - "Further, the study clearly shows that the new analogs are superior to native Mu1140 for the treatment of a systemic MRSA infection. " 01/01/2022 - "In this study, Mu1140 analogs were shown to be more effective than currently available treatments for systemic and skin MRSA infections. " 01/01/2009 - "Collectively, our findings illustrate the therapeutic potential of MU1140 for management of Gram-positive infections." 04/01/2015 - "The success of these agents as a novel treatment of MDR infections is exemplified by: the clinical development of MU1140 (mutacin 1140) and NAI-107 (microbisporicin), which are in late pre-clinical trials against gram-positive bacteria; NVB302 that has completed Phase I clinical trials for the treatment of Clostridium difficile infections and; duramycin that has completed Phase II clinical trials in the treatment of cystic fibrosis. "
2.	Cystic Fibrosis (Mucoviscidosis) 04/01/2015 - "The success of these agents as a novel treatment of MDR infections is exemplified by: the clinical development of MU1140 (mutacin 1140) and NAI-107 (microbisporicin), which are in late pre-clinical trials against gram-positive bacteria; NVB302 that has completed Phase I clinical trials for the treatment of Clostridium difficile infections and; duramycin that has completed Phase II clinical trials in the treatment of cystic fibrosis. "
3.	Clostridium Infections 04/01/2015 - "The success of these agents as a novel treatment of MDR infections is exemplified by: the clinical development of MU1140 (mutacin 1140) and NAI-107 (microbisporicin), which are in late pre-clinical trials against gram-positive bacteria; NVB302 that has completed Phase I clinical trials for the treatment of Clostridium difficile infections and; duramycin that has completed Phase II clinical trials in the treatment of cystic fibrosis. "
4.	Bacteremia 01/01/2022 - "In this study, the use of a combined formulation of the Mu1140 K2A and R13A analogs was shown to be more effective at treating MRSA bacteremia than the native Mu1140 or vancomycin. "
5.	Hypersensitivity (Allergy) 05/01/2010 - "Rapid injection of MU1140 was associated with a hypersensitivity reaction that can be blocked by premedication with diphenhydramine. "

Related Drugs and Biologics

1.	mutacin 1140
2.	microbisporicin
3.	duramycin
4.	Vancomycin
5.	Peptides (Polypeptides)
6.	Diphenhydramine (Benadryl)
7.	Bacteriocins (Lantibiotics)

Related Therapies and Procedures

1.	Premedication